Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: D.Lu who wrote (10258)	3/26/2010 8:57:18 AM
From: IRWIN JAMES FRANKEL	4 Recommendations Respond to of 10345

Hi D Lu, I do not think it will be hard to enroll. My wife was a Copaxone failure. Ifn antibodies degrading the utility of the other class of drug is just a matter of time and the higher the dose the shorter the time to resistance. It will take a long time to run the trial and get meaningful results. I wrote the rest of this post for IH, hope is of interest: Switching study - Copaxone to Tysabri My wife (who has RRMS) was on Copaxone for many years and did fairly well on it - that is until she had two serious exacerbations within one year. Her doctor pronounced the situation a treatment failure and suggested she shift to Tysabri. She has now been on T for over 2 years without any apparent exacerbation. I told the story of her progress in a series of posts that can be accessed here: Message 25078797 (By moving to the prior posts you can read the account.) From my wife's experience and what I hear about others who have moved to T after being treatment failures, this "switching" study will support the case for moving to T when other treatments fail. Unfortunately, it will take years for meaningful data. ij